Advocacy

ASGCT Holds Second Annual FDA Liaison Meeting

ASGCT Staff - December 11, 2019

ASGCT members presented on three topics to staff of the Office of Tissues and Advanced Therapies (OTAT), providing ASGCT recommendations to the Agency on regulatory topics of mutual interest in the field. Below, Wilson Bryan, MD, director of the FDA OTAT, acknowledges his staff during the discussion about common gene therapy IND deficiences and recommendations for improvement.

ASGCT held the second annual liaison meeting with the FDA’s Center for Biologics Evaluation and Research (CBER) on November 18. This year’s meeting was co-chaired by Adora Ndu, PharmD, J.D., chair of the ASGCT Regulatory Affairs Committee; and Maritza McIntyre, Ph.D., a member of both the ASGCT Board of Directors and the Regulatory Affairs Committee. ASGCT members presented on three topics to staff of the Office of Tissues and Advanced Therapies (OTAT), providing ASGCT recommendations to the Agency on regulatory topics of mutual interest in the field. In addition, OTAT staff provided useful information on common investigational new drug deficiencies and recommendations for improvement. View their presentation slides below.

Dan Levy, MD, PhD, Pfizer
Recommendations on Utilizing Surrogate Endpoints to Accelerate Development

Mike Havert, PhD, bluebird bio
Pre- and Post-Market Manufacturing Changes: Categorization of Major vs. Minor Changes and Requirements for Comparability Assessment for Gene Therapy Products

Anna Kwilas, PhD, Iwen Wu, PhD, and Ilan Irony, MD, FDA CBER OTAT
Common Gene Therapy IND Deficiencies and Recommendations for Improvement

Gabor Veres, PhD, BioMarin Pharmaceuticals
Development and Regulatory Considerations When Leveraging Platform Technology – Same/Similar Vector, Same/Similar Process, and Analytical Process

Read the summary of recommendations that ASGCT presenters provided to FDA.

Share This Page

Related Articles

Advocacy

Advocacy Reflects on Accomplishments and Looks Ahead to Future Efforts

ASGCT Staff - January 20, 2020

(From left) Michael C. Burgess, MD (R-TX) (with Matthew Porteus, M.D., Ph.D., and Jennelle Stephenson), and Danny K. Davis (D-IL), gave remarks emphasizing the importance of supporting sickle cell disease research.

Advocacy

ASGCT Co-Hosts Second Congressional Briefing on Sickle Cell Disease

ASGCT Staff - November 26, 2019
Advocacy

ASGCT Policy Summit Highlights Patient and Advocate Perspectives

ASGCT Staff - October 14, 2019

Rhoda Baer acquired from National Cancer Institute

Advocacy

Bridging the Gap Between Scientists And Patients In Gene Therapy Development

David Barrett, J.D. - September 27, 2019